147,943 Shares in Kura Oncology, Inc. (NASDAQ:KURA) Bought by Wealthfront Advisers LLC

Wealthfront Advisers LLC purchased a new stake in shares of Kura Oncology, Inc. (NASDAQ:KURA - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 147,943 shares of the company's stock, valued at approximately $1,289,000. Wealthfront Advisers LLC owned approximately 0.19% of Kura Oncology at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the business. Suvretta Capital Management LLC grew its holdings in shares of Kura Oncology by 8.2% during the third quarter. Suvretta Capital Management LLC now owns 7,652,782 shares of the company's stock valued at $149,535,000 after buying an additional 583,155 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Kura Oncology by 2.4% during the third quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company's stock valued at $34,798,000 after buying an additional 41,535 shares during the last quarter. Franklin Resources Inc. grew its holdings in shares of Kura Oncology by 1.5% during the third quarter. Franklin Resources Inc. now owns 1,588,401 shares of the company's stock valued at $28,687,000 after buying an additional 23,113 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Kura Oncology by 1.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 635,494 shares of the company's stock valued at $5,535,000 after buying an additional 10,542 shares during the last quarter. Finally, Alethea Capital Management LLC grew its holdings in shares of Kura Oncology by 108.2% during the third quarter. Alethea Capital Management LLC now owns 553,542 shares of the company's stock valued at $10,816,000 after buying an additional 287,636 shares during the last quarter.

Remove Ads

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. StockNews.com cut shares of Kura Oncology from a "buy" rating to a "hold" rating in a report on Tuesday. HC Wainwright reiterated a "buy" rating and set a $40.00 price objective on shares of Kura Oncology in a report on Thursday, February 27th. Bank of America dropped their price target on shares of Kura Oncology from $36.00 to $29.00 and set a "buy" rating on the stock in a research report on Friday, November 22nd. Wedbush reissued an "outperform" rating and set a $36.00 price target on shares of Kura Oncology in a research report on Thursday, February 27th. Finally, TD Cowen reissued a "buy" rating on shares of Kura Oncology in a research report on Thursday, November 21st. Four investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Kura Oncology currently has an average rating of "Moderate Buy" and a consensus target price of $25.50.

Insiders Place Their Bets

In other news, insider Mollie Leoni sold 4,963 shares of the business's stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the sale, the insider now owns 88,253 shares of the company's stock, valued at $694,551.11. The trade was a 5.32 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Thomas James Doyle sold 4,949 shares of the business's stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $38,948.63. Following the completion of the sale, the senior vice president now directly owns 88,193 shares in the company, valued at approximately $694,078.91. This trade represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 11,729 shares of company stock valued at $92,307. Company insiders own 5.50% of the company's stock.

Kura Oncology Stock Performance

KURA stock traded down $0.07 during mid-day trading on Wednesday, hitting $7.27. The company had a trading volume of 690,712 shares, compared to its average volume of 1,055,830. The firm has a market cap of $587.09 million, a PE ratio of -3.08 and a beta of 0.85. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. Kura Oncology, Inc. has a 12 month low of $6.79 and a 12 month high of $23.48. The stock's fifty day moving average price is $7.82 and its two-hundred day moving average price is $12.65.

Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.43. The company had revenue of $53.88 million during the quarter, compared to the consensus estimate of $57.96 million. On average, analysts forecast that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.